0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > VEGF165

VEGF165

VEGF165 Molecule Information

Name:Vascular endothelial growth factor A
Target Synonym:Vascular endothelial growth factor A;VEGF;VEGF-A;Vascular permeability factor;VPF;VEGFA
Number of Launched Drugs:15
Number of Drugs in Clinical Trials:80
Lastest Research Phase:Approved

VEGF165 Protein Product ListCompare or Buy

VEGF165 Molecule Synonym Name

RP1-261G23.1,MGC70609,MVCD1,VEGFA,VPF

VEGF165 Molecule Background

VEGF165 is the most abundant splice variant of VEGF-A. VEGF165 is produced by a number of cells including endothelial cells, macrophages and T cells. VEGF165 is involved in angiogenesis, vascular endothelial cell survival, growth, migration and vascular permeability. VEGF gene expression is induced by hypoxia, inflammatory cytokines and oncogenes. VEGF165 binds to heparan sulfate and is retained on the cell surface and in the extracellular matrix. VEGF165 binds to the receptor tyrosine kinases, VEGFR1 and VEGFR2. VEGF165 is the only splice variant that binds to co-receptors NRP-1 and NRP-2 that function to enhance VEGFR2 signaling. Binding of VEGF165 to VEGFR1 and VEGFR2 leads to activation of the PI3K/AKT, p38 MAPK, FAK and paxillin. VEGF plays a key role in tumor angiogenesis in many cancers.

VEGF165 References

VEGF165 Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Bevacizumab-awwb ABP-215,ABP215 Approved Amgen, Allergan, Daiichi Sankyo MVASI fda Non small cell lung cancer (NSCLC), Renal cell carcinoma, Metastatic colorectal cancer (CRC), Glioblastoma, Cervical carcinoma AMGEN INC 2017-09-14 Non small cell lung cancer (NSCLC), Renal cell carcinoma, Metastatic colorectal cancer (CRC), Glioblastoma, Cervical carcinoma Details
Bevacizumab biosimilar (Pfizer) PF-06439535; PF-6439535 Approved Pfizer bevacizumab ema Pfizer Europe MA EEIG 2019-02-14 Non small cell lung cancer (NSCLC), Breast cancer, Colorectal cancer, Glioblastoma, Renal carcinoma, Cervical carcinoma Details
Conbercept KH-902; FP-3 Approved Chengdu Kanghong Biotechnology Conbercept Ophthalmic Injection cfda Age-related macular degeneration (AMD), Diabetic macular edema, Choroidal neovascularisation 2018-05-29 Age-related macular degeneration (AMD), Macular degeneration Details
Aflibercept BAY-865321; BAT-86-5321 Approved Regeneron Pharmaceutical, Bayer, Santen EYLEA fda Macular edema, Macular degeneration REGENERON PHARMACEUTICALS 2011-11-18 Macular edema, Macular degeneration Details
Brolucizumab RTH-258; ESBA-1008; AL-86810; DLX-1008; XSZ53G39H5 (UNII code),RTH258,ESBA1008,AL86810 Approved Alcon BEOVU fda Wet age-related macular degeneration NOVARTIS PHARMS CORP 2019-10-07 Age-related macular degeneration (AMD) Details
Bevacizumab biosimilar (Intas Pharmaceuticals) Approved Intas Biopharmaceuticals Non small cell lung cancer (NSCLC) Details
Bevacizumab biosimilar (Biocad) BCD-021,BCD021; BCD 021 Approved Biocad Bevacizumab biosimilar (Biocad) 日本 Abscesses 北京强新生物科技 2010-11-25 00:00:00.0 Epithelial ovarian cancer, Non small cell lung cancer (NSCLC), Renal cell carcinoma, Colorectal cancer, Glioblastoma Details
Bevacizumab biosimilar (Hetero Drugs) Approved Hetero Drugs Colorectal cancer Details
Bevacizumab biosimilar (Biocon/Mylan) MYL-1402O,MYL1402O; MYL 1402O Approved Biocon, Mylan Brain cancer, Non small cell lung cancer (NSCLC), Metastatic renal cell carcinoma, Metastatic colorectal cancer (CRC), Ovarian cancer, Cervical carcinoma Details
Bevacizumab G180CL; G180CU; G180DL; RG-435; RO-4876646; NSC-704865; R-435 Approved Genentech, Chugai AVASTIN fda Glioblastoma multiforme, Non small cell lung cancer (NSCLC), Renal cell carcinoma, Ovarian cancer GENENTECH 2004-02-26 Primary peritoneal cancer, Glioma, Fallopian tube cancer, Glioblastoma multiforme, Non small cell lung cancer (NSCLC), Renal cell carcinoma, Breast cancer, Colorectal cancer, Glioblastoma, Ovarian cancer, Cervical carcinoma, Malignant glioma Details
Ziv-aflibercept AVE-0005; BAY-865321 Approved Regeneron Pharmaceutical, Sanofi, Yakult ZALTRAP fda Metastatic colorectal cancer (CRC) SANOFI AVENTIS US 2012-08-03 Colorectal cancer, Metastatic colorectal cancer (CRC) Details
Ranibizumab biosimilar (Intas Biopharmaceuticals) Approved Intas Biopharmaceuticals Wet age-related macular degeneration Details
Bevacizumab Biosimilar (AXXO) Approved AXXO Non small cell lung cancer (NSCLC), Metastatic colorectal cancer (CRC) Details
Bevacizumab biosimilar (Zydus Cadila) FKB-238 Approved Zydus cadila Non small cell lung cancer (NSCLC) Details
Ranibizumab AMD-Fab; rhuFab-V2; RFB-002; RG-3645; Y-0317; AMD-rhuFab-V2; rhu-Fab-VEG Approved Genentech, Novartis LUCENTIS fda Macular degeneration GENENTECH 2006-06-30 Macular edema, Retinal vein occlusion, Choroidal neovascularisation, Diabetic macular edema, Macular degeneration Details

VEGF165 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Abicipar pegol AGN-150998; MP-0112 BLA Filing Molecular Partners, Allergan Age-related macular degeneration (AMD), Diabetic macular edema Details
Bevacizumab biosimilar (Hualan Biological Engineering) WBP-264 Phase Ⅰ Hualan Biological Engineering Non small cell lung cancer (NSCLC), Metastatic colorectal cancer (CRC) Details
Ranibizumab biosimilar (CJ HealthCare) CJ-40012 Preclinical CJ HealthCare Age-related macular degeneration (AMD) Details
DE-120 DE-120,DE120 Phase Ⅱ Santen Age-related macular degeneration (AMD) Details
Bevacizumab biosimilar (Centus Biotherapeutics) FKB-238 Phase Ⅲ Fujifilm Kyowa Kirin Biologics, Centus Biotherapeutics Non small cell lung cancer (NSCLC), Solid tumours Details
Bevacizumab biosimilar (Alphamab/R-Pharm) RPH-001 Phase Ⅲ Alphamab, R-Pharm Colorectal cancer Details
Faricimab RG-7716; RO-6867461 Phase Ⅲ Roche Diabetic macular edema, Wet age-related macular degeneration Details
CLS-1002 CLS-1002 Phase Ⅰ Clearside Biomedical Age-related macular degeneration (AMD) Details
AAV2sFLT01 (Applied Genetic Technologies/Genzyme) AAV2-sFLT01; GZ-402663; sFLT-01 Phase Ⅰ Applied Genetic, Genzyme, JDRF Age-related macular degeneration (AMD) Details
Bevacizumab biosimilar (AryoGen Biopharma) Phase Ⅲ AryoGen Biopharma Colorectal cancer Details
Bevacizumab biosimilar (Biocnd) BCD-500 Phase Ⅲ Biocnd Cancer Details
Bevacizumab biosimilar (Synermore Biologics) SYN-050 Phase Ⅰ Synermore Biologics, Lonn Ryonn Pharma Solid tumours Details
Bevacizumab biosimilar (Jiangsu Hengrui Medicine) BP-102 Phase Ⅱ Jiangsu Hengrui Medicine Non small cell lung cancer (NSCLC), Metastatic colorectal cancer (CRC) Details
Muparfostat sodium PI-88 Phase Ⅲ Australian National University, TBG Diagnostics, Medigen Biotechnology Liver cancer Details
BI-695502 BI-695502,BI695502 Phase Ⅲ Boehringer Ingelheim Brain cancer, Non small cell lung cancer (NSCLC), Solid tumours, Colorectal cancer Details
Intravitreal ranibizumab (Sultan Qaboos University) Phase Ⅱ Sultan Qaboos University Retinal dystrophies Details
OB-318 OB-318 Phase Ⅰ Oneness Biotech Hepatocellular carcinoma (HCC) Details
Vascular endothelial growth factor gene therapy (Valentis) Phase Ⅱ Valentis, University of Eastern Finland Peripheral vascular disorders, ischaemic heart disorder Details
Bevacizumab biosimilar (Samsung Bioepis) SB-8; SP-8 BLA Filing Samsung Bioepis, 3SBio Non small cell lung cancer (NSCLC) Details
MP-0250 MP-0250 Phase Ⅱ Molecular Partners Non small cell lung cancer (NSCLC), hematological malignancies, Solid tumours Details
Bevacizumab biosimilar (Celltrion) CT-16; CTP-16 Phase Ⅲ Celltrion, Hospira Non small cell lung cancer (NSCLC), Colorectal cancer Details
NT-503 NT-503; NT-503-2; NT-503-3; NT-503-ECT Phase Ⅱ Neurotech Pharmaceuticals Age-related macular degeneration (AMD), Choroidal neovascularisation Details
Aflibercept biosimilar (Momenta/Mylan) M-710; MYL-1701P Phase Ⅲ Momenta, Mylan Diabetic macular edema Details
SNN-0029 sNN-0029 Phase Ⅱ Newron Pharmaceutical Amyotrophic lateral sclerosis (ALS) Details
Palomids P-52901; P-529; Palomid-529; RES-529; SG-00529,SG00529,RES529,Palomid529 Phase Ⅰ Diffusion Pharmaceuticals Age-related macular degeneration (AMD) Details
Ranibizumab biosimilar (Reliance Life Sciences Group) R-TPR-024 Phase Ⅲ Reliance Life Sciences Age-related macular degeneration (AMD) Details
Eylea Biosimilar (Alteogen) ALT-L9 Phase Ⅰ Alteogen, Kissei Pharmaceutical Wet age-related macular degeneration Details
Ranibizumab biosimilar (Xbrane) Phase Ⅲ Xbrane Biopharma Wet age-related macular degeneration Details
AG-13958 AG-013958; AG-13958 Phase Ⅱ Pfizer Age-related macular degeneration (AMD) Details
Bevacizumab biosimilar (JHL Biotech) JHL-1149 Phase Ⅰ JHL Biotech Lung cancer, Metastatic colorectal cancer (CRC), Ovarian cancer Details
Vanucizumab RG-7221; RO-5520985; B800Z06O8K (UNII code),RG7221; RO5520985 Phase Ⅱ Roche Solid tumours, Colorectal cancer Details
Recombinant anti-VEGF humanized monoclonal antibody (Jiangsu Aosaikang Pharmaceutical) ASK-1202; AMD-B Phase Ⅰ Jiangsu Aosaikang Pharmaceutical, AskGene Pharma Metastatic colorectal cancer (CRC) Details
AAV.7m8-aflibercept (Adverum Biotechnologies) ADVM-022 Phase Ⅰ Adverum Biotechnologies Wet age-related macular degeneration Details
Bevacizumab biosimilar (Prestige BioPharma/Hanwha Biologics) HD-204 Phase Ⅲ Hanwha Biologics, Prestige BioPharma, Alvogen Non small cell lung cancer (NSCLC), Solid tumours Details
Ethyl acetate extract ALS-L1023 Phase Ⅲ AngioLab Inc, Hanmi Obesity Details
Ranibizumab biosimilar (Formycon/Bioeq) FYB-201 Phase Ⅲ Formycon, Santo Holding GmbH Wet age-related macular degeneration Details
Sevacizumab APX-003; BD-0801; EPI-0030; SIM-BD-0801; TK-001 Phase Ⅰ Epitomics, Apexigen, Jiangsu T-mab BioPharma, Simcere Colorectal cancer, Ovarian cancer, Wet age-related macular degeneration, Hematological cancer Details
Bevacizumab biosimilar (Beijing Mabworks Biotech) MIL-60,MIL60; MIL 60 Phase Ⅲ Beijing Mabworks Biotech, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Betta Advanced non-squamous non small cell lung cancer (NSCLC) Details
Bevacizumab biosimilar (Bionovis/The Instituto Vital Brazil) Phase Not Specified Bionovis, The Instituto Vital Brazil Non small cell lung cancer (NSCLC), Metastatic renal cell carcinoma, Metastatic colorectal cancer (CRC), Metastatic breast cancer Details
Aflibercept biosimilar (Qilu Pharmaceutical) QL-1207 Phase Ⅲ Qilu Pharmaceutical Diabetic macular edema, Wet age-related macular degeneration Details
RPI-4610 RPI-4610 Phase Ⅱ Merck Sharp & Dohme Breast cancer, Solid tumours, Colorectal cancer Details
ARQ-736 ARQ-736 Phase Ⅰ ArQule Solid tumours Details
AZD-8601 AZD-8601; mRNA-AZD-8601 Phase Ⅱ AstraZeneca, Moderna Therapeutics Heart failure Details
Vascular endothelial growth factor gene therapy (Biosidus S.A.) Phase Ⅰ Biosidus ischaemic heart disorder Details
VEGF activator zinc finger protein hVEGF-A; SB-509 Phase Ⅱ Sangamo BioSciences Amyotrophic lateral sclerosis (ALS) Details
AVA-001(Adverum biotechnologies) AVA-001 Phase Ⅱ Adverum Biotechnologies Wet age-related macular degeneration Details
ASC-06 ALN-VSP; ALN-VSP01; ALN-VSP02; ASC-06,ALNVSP01; ALNVSP02; ASC06 Phase Ⅰ Alnylam, Ascletis Liver cancer Details
Bevacizumab biosimilar (Boan Biopharma) LY-01008 Phase Ⅲ Shandong Boan Biotechnology, Luye Pharma Non small cell lung cancer (NSCLC), Colorectal neoplasms Details
Ranibizumab biosimilar (CJSC Generium) GNR-067 Phase Ⅰ CJSC Generium Wet age-related macular degeneration Details
Aflibercept/Rinucumab REGN-2176-3 Phase Ⅱ Bayer, Regeneron Pharmaceutical Wet age-related macular degeneration Details
Bevacizumab biosimilar (Cipla BioTec) CBT-124 Phase Ⅲ Cipla Non small cell lung cancer (NSCLC) Details
Colorectal cancer vaccine (Immunovo/Pepscan Therapeutics) Phase Ⅰ Pepscan Systems, VU University Medical Center, Immunovo Colorectal cancer Details
PTC-299 PTC-299 Phase Ⅱ PTC Therapeutics Neurofibromatosis, Solid tumours, Central nervous system leukemia Details
Bevacizumab biosimilar (Tanvex BioPharma) TX-16 Phase Ⅰ Tanvex BioPharma Metastatic colorectal cancer (CRC) Details
Ranibizumab biosimilar (Senju) GBS-007 Phase Ⅲ Senju Pharmaceutical Age-related macular degeneration (AMD) Details
Bevacizumab biosimilar (Eastern Biotech) JY-028 Phase Ⅰ Eastern Biotech Non small cell lung cancer (NSCLC), Metastatic colorectal cancer (CRC) Details
NM-3 NM-3 Phase Ⅰ Mercian, Genzyme Solid tumours, Rheumatoid arthritis (RA) Details
Ranibizumab biosimilar (Samsung Bioepis) SB-11 Phase Ⅲ Samsung Bioepis, C-Bridge Capital Partners Age-related macular degeneration (AMD) Details
Dilpacimab ABT-165; DVD-Ig ABT-165 Phase Ⅱ Abbvie Colorectal cancer Details
XL-820 XL-820 Phase Ⅱ Exelixis Gastrointestinal stromal tumors (GISTs) Details
MV-833 Phase Ⅰ Toagosei, PDL BioPharma Solid tumours Details
Ranibizumab biosimilar (Qilu Pharmaceutical) BCD-300; QL-1205 Phase Ⅲ Qilu Pharmaceutical, Biocnd Wet age-related macular degeneration Details
Bevacizumab biosimilar (Reliance Life Sciences) R-TPR-023 Phase Ⅲ Reliance Life Sciences Colorectal cancer Details
Bevacizumab biosimilar (Gedeon Richter) Phase Ⅰ Gedeon Richter Cancer Details
Varisacumab AT-001-IBCG; GNR-011; R-84 Phase Ⅲ Peregrine, University of Texas Southwestern Medical Center, Affitech Non small cell lung cancer (NSCLC), Breast cancer, Eye disorders, Colorectal cancer, Glioblastoma Details
Ranibizumab biosimilar (Pfenex) PF-582 Phase Ⅱ Pfenex Wet age-related macular degeneration Details
LMG-324 LMG-324 Phase Ⅱ Alcon Age-related macular degeneration (AMD) Details
Colorectal cancer vaccine (Pepscan Systems) Phase Ⅰ Pepscan Systems Colorectal cancer Details
Aflibercept/Nesvacumab REGN 910-3 Phase Ⅱ Regeneron Pharmaceutical, Bayer Diabetic macular edema, Wet age-related macular degeneration Details
Bevacizumab biosimilar (Shanghai Henlius Biotech) HLX-04 Phase Ⅲ Shanghai Henlius Biotech Non small cell lung cancer (NSCLC), Metastatic colorectal cancer (CRC) Details
LHA-510 LHA-510 Phase Ⅱ Alcon Wet age-related macular degeneration Details
Bevacizumab biosimilar (CTTQ Pharma) TQ-B2302 Phase Ⅲ Chiatai Tianqing (CTTQ) Non small cell lung cancer (NSCLC) Details
TAB-008 TAB-008; TOT-102 Phase Ⅲ TOT Biopharm Non small cell lung cancer (NSCLC) Details
Bevacizumab biosimilar (Dr. Reddy's Laboratories) Phase Ⅲ Dr Reddys Laboratories Glioma, Fallopian tube cancer, Non small cell lung cancer (NSCLC), Renal cell carcinoma, Breast cancer, Colorectal cancer, Peritoneum cancer, Ovarian cancer, Cervical carcinoma Details
Ranibizumab biosimilar (Shanghai United Cell Biotechnology) Phase Ⅰ Shanghai United Cell Biotechnology Macular edema Details
Bevacizumab biosimilar (Oncobiologics) ONS-1045; ONS-5010 Phase Ⅲ Outlook Therapeutics, Ipca Labs, Liomont, Huahai Pharmaceutical, Viropro, Boston Oncology, BioLexis Pte Wet age-related macular degeneration, Cancer Details
PRS-050 PRS-050; PRS-050-PEG40 Phase Ⅰ Pieris Pharmaceuticals Solid tumours Details
AdvVEGF-D therapy (University of Eastern Finland) EG-013; Ad.VEGF-DdeltaNdeltaC Phase Ⅱ University of Eastern Finland Angina pectoris Details
Bevacizumab biosimilar (Innovent Biologics) IBI-305,IBI305,IBI 305 BLA Filing Innovent Biologics Non small cell lung cancer (NSCLC), Colorectal neoplasms Details
Ranibizumab biosimilar (Chong Kun Dang Pharmaceutical) CKD-701 Preclinical Chong Kun Dang Age-related macular degeneration (AMD) Details

This web search service is supported by Google Inc.

totop